The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke

J Neuroinflammation. 2019 Nov 28;16(1):242. doi: 10.1186/s12974-019-1638-6.

Abstract

Background: Preserving the integrity of the blood-brain barrier (BBB) is beneficial to avoid further brain damage after acute ischemic stroke (AIS). Astrocytes, an important component of the BBB, promote BBB breakdown in subjects with AIS by secreting inflammatory factors. The glucagon-like peptide-1 receptor (GLP-1R) agonist exendin-4 (Ex-4) protects the BBB and reduces brain inflammation from cerebral ischemia, and GLP-1R is expressed on astrocytes. However, the effect of Ex-4 on astrocytes in subjects with AIS remains unclear.

Methods: In the present study, we investigated the effect of Ex-4 on astrocytes cultured under oxygen-glucose deprivation (OGD) plus reoxygenation conditions and determined whether the effect influences bEnd.3 cells. We used various methods, including permeability assays, western blotting, immunofluorescence staining, and gelatin zymography, in vitro and in vivo.

Results: Ex-4 reduced OGD-induced astrocyte-derived vascular endothelial growth factor (VEGF-A), matrix metalloproteinase-9 (MMP-9), chemokine monocyte chemoattractant protein-1 (MCP-1), and chemokine C-X-C motif ligand 1 (CXCL-1). The reduction in astrocyte-derived VEGF-A and MMP-9 was related to the increased expression of tight junction proteins (TJPs) in bEnd.3 cells. Ex-4 improved neurologic deficit scores, reduced the infarct area, and ameliorated BBB breakdown as well as decreased astrocyte-derived VEGF-A, MMP-9, CXCL-1, and MCP-1 levels in ischemic brain tissues from rats subjected to middle cerebral artery occlusion. Ex-4 reduced the activation of the JAK2/STAT3 signaling pathway in astrocytes following OGD.

Conclusion: Based on these findings, ischemia-induced inflammation and BBB breakdown can be improved by Ex-4 through an astrocyte-dependent manner.

Keywords: Astrocyte; Blood-brain barrier; Exendin-4; Ischemic stroke; Oxygen-glucose deprivation.

MeSH terms

  • Animals
  • Astrocytes / drug effects*
  • Astrocytes / metabolism
  • Blood-Brain Barrier / drug effects*
  • Blood-Brain Barrier / pathology
  • Chemokine CCL2 / metabolism
  • Chemokine CXCL1 / metabolism
  • Exenatide / pharmacology*
  • Exenatide / therapeutic use
  • Glucagon-Like Peptide-1 Receptor / agonists*
  • Infarction, Middle Cerebral Artery / metabolism*
  • Infarction, Middle Cerebral Artery / pathology
  • Inflammation / drug therapy*
  • Inflammation / metabolism
  • Inflammation / pathology
  • Male
  • Matrix Metalloproteinase 9 / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Stroke / metabolism*
  • Stroke / pathology
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Chemokine CCL2
  • Chemokine CXCL1
  • Glucagon-Like Peptide-1 Receptor
  • Vascular Endothelial Growth Factor A
  • Exenatide
  • Matrix Metalloproteinase 9